Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 3/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2781321 | 1.00 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2RORCF10 | |
| SCHEMBL190976 | 1.00 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2RORCF10 | |
| SCHEMBL1972348 | 1.00 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2RORCF10 | |
| SCHEMBL1977849 | 1.00 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2RORCF10 | |
| SCHEMBL190977 | 1.00 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2RORCF10 | |
| SCHEMBL2226084 | 1.00 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2RORCF10 | |
| SCHEMBL30693235 | 1.00 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2RORCF10 | |
| SCHEMBL1892809 | 0.90 | SLC6A4 (0.47) | SLC6A3SLC6A4SLC6A2RORCF10 | |
| SCHEMBL2354780 | 0.90 | SLC6A4 (0.47) | SLC6A3SLC6A4SLC6A2RORCF10 | |
| SCHEMBL1974759 | 0.90 | SLC6A4 (0.47) | SLC6A3SLC6A4SLC6A2RORCF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398768-B1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| US-8318759-B2 | Pyrrolidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2398768-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| EP-2185540-B1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010094667-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | SLC6A3 6/4885SLC6A4 202/4885SLC6A2 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.